CLYM

Climb Bio (CLYM)

About Climb Bio (CLYM)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Details

Daily high

$7.10

Daily low

$6.37

Price at open

$6.77

52 Week High

$8.04

52 Week Low

$1.05

Market cap

312.4M

Dividend yield

0.00%

Volume

516,401

Avg. volume

636,463

P/E ratio

-7.38

Climb Bio News